Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 5/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20475037 | 0.87 | TP53 (0.41) | SMN1; SMN2ALDH1A1CES2CES1LMNA | |
| SCHEMBL3579412 | 0.79 | RXFP1 (0.44) | SMN1; SMN2ALDH1A1LMNASLC6A2SLC6A4 | |
| SCHEMBL4672830 | 0.70 | CES2 (0.52) | ALDH1A1CES2CES1ACKR3L3MBTL1 | |
| SCHEMBL4670556 | 0.70 | CES2 (0.45) | CES2CES1DPP4SLC6A2SLC6A4 | |
| SCHEMBL4670554 | 0.70 | CES2 (0.45) | CES2CES1DPP4ACKR3SLC6A2 | |
| Hydrochloric Acid SCHEMBL1836446 | 0.69 | CES2 (0.50) | ALDH1A1CES2CES1ACKR3L3MBTL1 | |
| SCHEMBL4782622 | 0.66 | RAB9A (0.48) | SMN1; SMN2ALDH1A1LMNASLC6A2SLC6A4 | |
| SCHEMBL8229680 | 0.65 | L3MBTL1 (0.44) | CES2CES1ACKR3SLC6A2SLC6A4 | |
| SCHEMBL14350907 | 0.65 | L3MBTL1 (0.48) | CES2CES1ACKR3SLC6A2SLC6A4 | |
| SCHEMBL1727139 | 0.65 | DPP4 (0.51) | SMN1; SMN2ALDH1A1DPP4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759363-B2 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. (US) | 2010-07-20 | — | — | US | claimed |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. | 2006-11-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | HTR4, HTR1A, HTR5A | SMN1; SMN2 2098/4885ALDH1A1 1216/4885CES2 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.